Charles Bennett to Adverse Drug Reaction Reporting Systems
This is a "connection" page, showing publications Charles Bennett has written about Adverse Drug Reaction Reporting Systems.
Connection Strength
3.773
-
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. Expert Opin Drug Saf. 2016 Aug; 15(8):1003-11.
Score: 0.508
-
Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov; 38(8):905-7.
Score: 0.394
-
Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. Expert Opin Drug Saf. 2011 Jul; 10(4):521-8.
Score: 0.357
-
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res. 2009 Jun 01; 15(11):3850-5.
Score: 0.311
-
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol. 2007 Sep 18; 50(12):1138-43.
Score: 0.276
-
Systematic review of piperacillin-induced neutropenia. Drug Saf. 2007; 30(4):295-306.
Score: 0.263
-
The Research on Adverse Drug Events and Reports (RADAR) project. JAMA. 2005 May 04; 293(17):2131-40.
Score: 0.235
-
Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke. 2004 Feb; 35(2):533-7.
Score: 0.214
-
Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol. 2003 Oct 15; 21(20):3859-66.
Score: 0.211
-
Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions. PLoS One. 2019; 14(7):e0219521.
Score: 0.157
-
Fluoroquinolone-associated suicide. Eur J Intern Med. 2018 09; 55:e21-e22.
Score: 0.147
-
Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry. Leuk Res. 2016 May; 44:61-4.
Score: 0.125
-
Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system. Expert Opin Drug Saf. 2015; 14(11):1653-60.
Score: 0.121
-
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009 Aug; 10(8):816-24.
Score: 0.079
-
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009 May 14; 113(20):4834-40.
Score: 0.077
-
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl. 2009 Feb; (112):S20-4.
Score: 0.076
-
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008 Dec; 9(12):1166-72.
Score: 0.075
-
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. Best Pract Res Clin Haematol. 2005; 18(3):481-9.
Score: 0.057
-
Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004 Sep 30; 351(14):1403-8.
Score: 0.056
-
Evaluation of a potential clinical interaction between ceftriaxone and calcium. Antimicrob Agents Chemother. 2010 Apr; 54(4):1534-40.
Score: 0.020
-
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007 May; 31(5):599-604.
Score: 0.016